Compare AGNT & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGNT | ESPR |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | 1834 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 846.3M | 816.9M |
| IPO Year | N/A | 2013 |
| Metric | AGNT | ESPR |
|---|---|---|
| Price | $4.96 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 1.5M | ★ 8.9M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $4.51 | $1.10 |
| 52 Week High | $5.79 | $4.18 |
| Indicator | AGNT | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 64.61 |
| Support Level | N/A | $3.16 |
| Resistance Level | $5.79 | $3.18 |
| Average True Range (ATR) | 0.32 | 0.02 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 32.68 | 87.50 |
AGNT Inc is a multi-model real estate platform, with brands including eXp Realty, eXp Commercial, NextHome, FrameVR.io, and SUCCESS Enterprises. The group prioritizes transparency, innovation, and long-term value for agents, franchise owners, staff, and shareholders.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.